Clinical trial Recruiting at 1 site Observational Ages 18 and up

Factors Influencing Outcomes in ECMO and Impella Patients

Official title: Investigation of Factors Influencing Outcomes in Patients Requiring ECMO and Impella Support, With Special Focus on Their Metabolic and Thyroid Hormone Changes (Az ECMO és Impella kezelést igénylő Betegek kimenetelét befolyásoló tényezők vizsgálata, különös Tekintettel Metabolikus és Pajzsmirigyhormon változásaikra)

Run by Gottsegen National Cardiovascular Institute · NCT07885618 · Data updated 2026-11-12

This study tests whether metabolic and thyroid hormone changes help predict survival for adults on ECMO or Impella at a single Hungarian cardiac ICU.

More Critical Illness trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment160 (estimated)
SponsorGottsegen National Cardiovascular Institute
Academic / other
Locations1 site (Budapest)
StatusRecruiting
StartedAugust 17, 2026
Main results expectedJune 30, 2030
Study endsDecember 31, 2030
Registry record updatedOctober 21, 2026
Trial IDNCT07885618 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with ECMO and/or Impella support in the cardiovascular ICU who (or whose legal representative) can provide informed consent.

Probably not a fit

Patients not experiencing metabolic or thyroid disturbances related to critical illness may have limited direct benefit from this observational work.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-center observational study follows adults treated with temporary mechanical circulatory support (ECMO or Impella) to see how metabolic status and thyroid hormone dynamics relate to 28-day and ICU mortality and other outcomes. Researchers collect medical history, nutritional status, functional capacity, and serial laboratory data including thyroid axis hormones, blood gases, and coagulation profiles. The aim is to identify independent predictors of mortality and characterize cardiac and non-cardiac complications and nutritional changes during critical illness. The study emphasizes non-cardiac factors such as endocrine dysfunction and nutritional status as potential drivers of outcomes in severe cardiogenic shock. Enrollment includes consecutive eligible patients with consent, making this a real-world cohort assessment in a high-volume center.

Why it matters

Potential benefit: If successful, findings could help clinicians identify at-risk patients earlier and tailor supportive care to improve survival and recovery.

How similar studies have gone: Previous work in critical illness has shown that non-cardiac factors like endocrine changes and nutritional status can influence outcomes, but studies in ECMO/Impella settings are less common.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients (age ≥ 18 years)
* Treatment with ECMO and/or Impella support
* Informed consent provided by the patients next of kin/ legal representative

Exclusion Criteria:

* None

Where it's running

  • Gottsegen Gyorgy National Cardiovascular Center
    Budapest, Hungary
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.